… Despite significant progress, metastatic urothelial cancer … mainstay of treatment for metastatic
disease, but immunotherapy, … , and future perspectives in metastatic urothelial carcinoma. …

… standard first-line treatment for patients with metastatic urothelial carcinoma. However, a
large proportion of patients with metastatic urothelial carcinoma are considered “unfit” for …

… for treating metastatic urothelial cancer in clinical practice. The paradigm of medical treatment
for patients with metastatic … for metastatic urothelial cancer, including ongoing clinical trials. …

… initial therapy for metastatic urothelial cancer (mUC). However, despite a response rate of
approximately 50%, a small proportion of patients with distant metastases may be cured by …

… is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and
… of metastatic urothelial cancer. TRANSITIONAL CELL cancer (TCC) of the urothelium is a …

Cisplatin-based chemotherapy is currently the first-line standard of care for patients with
metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for cisplatin, …

… with metastatic urothelial cancer underwent resection at our center. Although data are not
available regarding the exact number of patients treated with metastatic urothelial cancer at …

… from first-line treatment for metastatic urothelial cancer, included both cisplatin-eligible and
… of the prescribing label for atezolizumab for metastatic urothelial cancer in the first-line setting…

Purpose No standard therapy exists for metastatic urothelial cancer (UC) that has progressed
after initial chemotherapy. This trial was designed to assess the efficacy and tolerability of …

… Patients with previously treated progressive metastatic UC of the bladder, renal pelvis, ureter
or urethra, histologically confirmed at the Memorial Sloan-Kettering Cancer Center, were eligible …